Genmab — Juni 2024
-
Det er historien om igen, som f.eks dengang Novo faldt mere end den skulle. Der var kritik på kritik, og ingen (som i ingen ) spåede hverken dagens niveau, eller niveauet for 2 år siden.
-
@Hugininvest spot on
-
…så nu er det dem, der har været lidt kritiske overfor GEN, der er problemet…
-
Det har du ret i! Men uden kritikere, så var tulipaner stadig det vigtigste investeringaktiv, og vi ville ikke have kloakering…
-
Godmorgen
-
Completion of Share Buy-back Program https://proinvestor.com/investornyt/1178711/completion-of-share-buy-back-program
-
Epcoritamab (TEPKINLY
) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphom https://proinvestor.com/investornyt/1178791/epcoritamab-tepkinly-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-relapsed-refractory-follicular-lymphom -
Amivantamab plus lazertinib versus osimertinib : a secondary analysis from MARIPOSA https://www.annalsofoncology.org/article/S0923-7534(24)00702-6/fulltext https://www.nejm.org/doi/abs/10.1056/NEJMoa2403614
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind